Detalhe da pesquisa
1.
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.
Int J Clin Oncol
; 27(2): 383-395, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34973108
2.
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3.
Oncologist
; 26(7): e1143-e1155, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33955129
3.
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
Cancer Sci
; 111(3): 907-923, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31883418
4.
Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study.
BMC Cancer
; 19(1): 17, 2019 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30616534
5.
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.
Int J Clin Oncol
; 24(3): 262-273, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30392115
6.
Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.
Int J Clin Oncol
; 24(3): 274-287, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30515674
7.
Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.
Cancer Sci
; 109(3): 803-813, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29345736
8.
Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study.
Cancer Sci
; 108(6): 1231-1239, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28267243
9.
Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
Future Oncol
; 13(21): 1839-1852, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28707479
10.
Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients.
Cancer Sci
; 107(6): 755-63, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26991823
11.
Axitinib plasma pharmacokinetics and ethnic differences.
Invest New Drugs
; 33(2): 521-32, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25663295
12.
Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.
Jpn J Clin Oncol
; 45(5): 439-48, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25647781
13.
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
Cancer Sci
; 105(12): 1576-83, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25283266
14.
Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.
Invest New Drugs
; 30(3): 1055-64, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21301929
15.
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.
Liver Cancer
; 10(3): 249-259, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34239811
16.
Analysis of subsequent therapy in Japanese patients with hormone receptorâpositive/human epidermal growth factor receptor 2ânegative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
Breast Cancer
; 28(2): 335-345, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33085032
17.
Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients.
Cancer Sci
; 101(4): 963-8, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20180805
18.
Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study.
Cancer Med
; 9(14): 4929-4940, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32420697
19.
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Breast Cancer
; 26(5): 637-650, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31127500
20.
Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Breast Cancer
; 26(5): 651, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31168692